The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia

Journal of the American College of Cardiology

Volumn 40, Issue 7, 2002, Pages 1232-1240

  Halcox, Julian P J ^a   Nour, Khaled R A ^a   Zalos, Gloria ^a   Mincemoyer, Rita ^a   Waclawiw, Myron A ^a   Rivera, Candido E ^b   Willie, Georgia ^c   Ellahham, Samer ^c   Quyyumi, Arshed A ^a,d  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c WASHINGTON HOSPITAL CENTER   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ISOSORBIDE DINITRATE; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; VERAPAMIL;

ADULT; ARTICLE; BLOOD VESSEL TONE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPEREMIA; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; TREADMILL; VASODILATATION;

ADULT; AGED; BRACHIAL ARTERY; CASE-CONTROL STUDIES; CORONARY CIRCULATION; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; EXERCISE TEST; FEMALE; FLOW CYTOMETRY; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PLATELET ACTIVATION; VASODILATION; VASODILATOR AGENTS;

EID: 0037009979     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)02139-3     Document Type: Article

References (33)

1. Quyyumi AA. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998;105:32S-9S.
2. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995;95:1747-55.
3. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO III. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation 1995;92:320-6.
4. Joannides R, Haefeli WE, Linder L, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995;91:1314-9.
5. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84: 9265-9.
6. Diodati JG, Dakak N, Gilligan DM, Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998;98:17-24.
7. Andrews NP, Dakak N, Quyyumi AA. Platelet inhibitory effects of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol 2001;37:510-6.
8. Beavo JA. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 1995;75:725-48.
9. Doucette JW, Corl PD, Payne HM, et al. Validation of a Doppler guide wire for intravascular measurement of coronary artery flow velocity. Circulation 1992;85:1899-911.
10. Jackson G, Benjamin N, Jackson N, Allen MJ. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 1999;83:13C-20C.
11. Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000;101:2349-54.
12. Panza JA, Quyyumi AA, Diodati JG, Callahan TS, Bonow RO, Epstein SE. Long-term variation in myocardial ischemia during daily life in patients with stable coronary artery disease: its relation to changes in the ischemic threshold. J Am Coll Cardiol 1992;19:500-6.
13. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342:1622-6.
14. Adachi H, Nishino M. Coronary artery diameter increase induced by a phosphodiesterase 5 inhibitor, E4021, in conscious pigs. Jpn J Pharmacol 1998;77:99-102.
15. Kugiyama K, Yasue H, Ohgushi M, et al. Deficiency in nitric oxide bioactivity in epicardial coronary arteries of cigarette smokers. J Am Coll Cardiol 1996;28:1161-7.
16. Martin W, Furchgott RF, Villani GM, Jothianandan D. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther 1986;237: 539-47.
17. Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996;78:1210-4.
18. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
19. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51.
20. Chen Y, Du R, Traverse JH, Bache RJ. Effect of sildenafil on coronary active and reactive hyperemia. Am J Physiol Heart Circ Physiol 2000;279:H2319-25.
21. Wallace AW, Tom WL. Interaction of L-arginine and phosphodiesterase inhibitors in vasodilation of the porcine internal mammary artery. Anesth Anal 2000;90:840-6.
22. Delpy E, le Monnier de Gouville AC. Cardiovascular effects of a novel, potent and selective phosphodiesterase 5 inhibitor, DMPPO: in vitro and in vivo characterization. Br J Pharmacol 1996;118:1377-84.
23. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation 1988;77:43-52.
24. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate (see comments). Circulation 1990;81:850-9.
25. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation 1986;73:865-76.
26. Tousoulis D, Davies G, Tentolouris C, Crake T, Toutouzas P. Inhibition of nitric oxide synthesis during the cold pressor test in patients with coronary artery disease. Am J Cardiol 1997;79:1676-9.
27. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow- mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-51.
28. Ryningen A, Holmsen H. Biochemistry of platelet activation. In: Rao GHR, ed. Handbook of Platelet Physiology and Pharmacology. Boston, MA: Kluwer Academic Publishers, 1999;188-237.
29. Holmes MB, Sobel BE, Howard DB, Schneider DJ. Differences between activation thresholds for platelet P-selectin glycoprotein IIb-IIIa expression and their clinical implications. Thromb Res 1999; 95:75-82.
30. Gries A, Bode C, Peter K, et al. Inhaled nitric oxide inhibits human platelet aggregation, P-selectin expression, and fibrinogen binding in vitro and in vivo. Circulation 1998;97:1481-7.
31. Hagberg IA, Solvik UA, Opdahi H, Roald E, Lyberg T. Inhalation of nitric oxide inhibits ADP-induced platelet aggregation and α-granule release. Platelets 1999;10:382-90.
32. Wallis RM, Corbin JD, Francis SH, Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C-12C.
33. Phillips BG, Kato M, Pesek CA, et al. Sympathetic activation by sildenafil. Circulation 2000;102:3068-73.